Key result
Edoxaban showed no significant difference compared to dalteparin for cancer-associated VTE using a 10-outcome hierarchical win ratio approach.
Why the study?
Does edoxaban improve hierarchical clinical outcomes compared to dalteparin in patients with cancer-associated venous thromboembolism?
RCT (n=1,046)
Does edoxaban improve hierarchical clinical outcomes compared to dalteparin in patients with cancer-associated venous thromboembolism?
Answers are grounded in this paper and cite their sources.
A win ratio analysis of the Hokusai VTE Cancer trial confirms no significant difference in hierarchical clinical outcomes between edoxaban and dalteparin for cancer-associated VTE.
BACKGROUND: The Hokusai Venous Thromboembolism (VTE) Cancer trial demonstrated that edoxaban was noninferior to dalteparin for the treatment of cancer-associated venous VTE. OBJECTIVES: We reanalyzed the trial using the win ratio, an approach that evaluates a composite of outcomes in a hierarchical order. METHODS: Forty-nine thrombosis experts ranked 10 outcomes in order of clinical importance from all-cause death (most important) to clinically relevant nonmajor bleeding (least important). We performed unmatched pairwise comparisons between participants on edoxaban and those on dalteparin at 6- and 12-month follow-up. Within each pair, edoxaban was assigned a win, loss, or tie according to the hierarchy of outcomes. We calculated the win ratio (total wins divided by total losses among edoxaban patients), with more wins than losses indicating the benefit of edoxaban, and the win difference (total wins minus total losses). RESULTS: Among 273 528 pairs (522 × 524 participants), edoxaban was associated with a win in 34.9%, a loss in 38.5%, and a tie in 26.6%. The win ratio was 0.91 (95% CI, 0.76-1.08), with a win difference of -3.55% (95% CI, -9.9% to 2.9%) at 12 months. The win ratio remained unchanged at 6 months (0.91; 95% CI, 0.75-1.11). The findings were consistent with a hierarchy of only death, recurrent VTE, and major bleeding (win ratio, 0.92; 95% CI, 0.76-1.11), or when replacing all-cause death with VTE-related death or fatal bleeding (win ratio, 0.83; 95% CI, 0.65-1.06). CONCLUSION: We observed no significant difference between edoxaban and dalteparin for the treatment of cancer-associated VTE when using the win ratio approach with a hierarchy of 10 prioritized outcomes.
No takes yet. Share an insight, caveat, or question.
Es et al. (2025) conducted an RCT in Cancer-associated venous thromboembolism (n=1,046). Edoxaban vs. Dalteparin was evaluated on Composite of 10 outcomes in a hierarchical order evaluated by win ratio (Win ratio 0.91, 95% CI 0.76-1.08). Edoxaban showed no significant difference compared to dalteparin for cancer-associated VTE using a 10-outcome hierarchical win ratio approach.
Synapse has enriched 10 related papers. Consider them for comparative context: